Drug Name | Pathway ID | Pathway name | P-value | No. of gene members | UniProt AC | Gene name | Detail of Coexpression | |
---|
Flumazenil | hsa00190 | Oxidative phosphorylation | 3.56E-02 | 3 | Q16718, Q13488, O14521 | NDUFA5, TCIRG1, SDHD | More | | Flumazenil | hsa00230 | Purine metabolism | 1.81E-02 | 2 | P20839, Q02153 | IMPDH1, GUCY1B3 | More | | Flumazenil | hsa00260 | Glycine, serine and threonine metabolism | 1.99E-02 | 1 | P22557 | ALAS2 | More | | Flumazenil | hsa00380 | Tryptophan metabolism | 4.14E-02 | 1 | Q16613 | AANAT | More | | Flumazenil | hsa00512 | Mucin type O-glycan biosynthesis | 3.78E-02 | 2 | O95395, Q8N4A0 | GCNT3, GALNT4 | More | | Flumazenil | hsa00565 | Ether lipid metabolism | 3.94E-02 | 1 | Q8N661 | TMEM86B | More | | Flumazenil | hsa00630 | Glyoxylate and dicarboxylate metabolism | 4.29E-03 | 2 | P40925, P15104 | MDH1, GLUL | More | | Flumazenil | hsa00970 | Aminoacyl-tRNA biosynthesis | 3.78E-02 | 2 | O95363, Q15046 | FARS2, KARS | More | | Flumazenil | hsa03008 | Ribosome biogenesis in eukaryotes | 4.94E-02 | 2 | P19784, P67870 | CSNK2A2, CSNK2B | More | | Flumazenil | hsa03013 | RNA transport | 4.92E-03 | 9 | P52298, Q09161, O14893, Q7Z3B4, P35658, Q14152, O75822, P78345, Q9Y6A5 | NCBP2, NCBP1, GEMIN2, NUP54, NUP214, EIF3A, EIF3J, RPP38, TACC3 | More | | Flumazenil | hsa03040 | Spliceosome | 3.35E-07 | 14 | Q14562, O43143, O60508, P08579, P26368, Q13595, Q07955, Q01130, P84103, Q13243, P11142, Q9Y2W2, O43447, O75643 | DHX8, DHX15, CDC40, SNRPB2, U2AF2, TRA2A, SFRS1, SFRS2, SFRS3, SFRS5, HSPA8, WBP11, PPIH, ASCC3L1 | More | | Flumazenil | hsa03050 | Proteasome | 9.50E-04 | 1 | P55036 | PSMD4 | More | | Flumazenil | hsa04014 | Ras signaling pathway | 2.36E-02 | 8 | P42338, P20827, P49767, Q13009, Q7LDG7, P63218, P50151, P19174 | PIK3CB, EFNA1, VEGFC, TIAM1, RASGRP2, GNG5, GNG10, PLCG1 | More | | Flumazenil | hsa04015 | Rap1 signaling pathway | 1.79E-02 | 8 | P20827, P49767, Q96FS4, P11215, Q13009, Q7LDG7, P42338, P19174 | EFNA1, VEGFC, SIPA1, ITGAM, TIAM1, RASGRP2, PIK3CB, PLCG1 | More | | Flumazenil | hsa04024 | cAMP signaling pathway | 4.25E-03 | 7 | P63092, P42338, P26678, P0DP23, P61586, Q13370, Q13009 | GNAS, PIK3CB, PLN, CALM1, RHOA, PDE3B, TIAM1 | More | | Flumazenil | hsa04062 | Chemokine signaling pathway | 9.23E-03 | 10 | P09769, P07948, P42338, P19174, P63218, P50151, P43250, Q7LDG7, Q13009, Q8WYR1 | FGR, LYN, PIK3CB, PLCG1, GNG5, GNG10, GRK6, RASGRP2, TIAM1, PIK3R5 | More | | Flumazenil | hsa04064 | NF-kappa B signaling pathway | 1.91E-04 | 12 | P10415, Q13489, P25963, P51617, O00463, P01375, Q04759, Q9UDY8, Q13077, Q16548, Q13315, P24522 | BCL2, BIRC3, NFKBIA, IRAK1, TRAF5, TNF, PRKCQ, MALT1, TRAF1, BCL2A1, ATM, GADD45A | More | | Flumazenil | hsa04070 | Phosphatidylinositol signaling system | 4.86E-02 | 3 | P0DP23, P42338, P27987 | CALM1, PIK3CB, ITPKB | More | | Flumazenil | hsa04071 | Sphingolipid signaling pathway | 9.39E-03 | 7 | P17252, P21453, Q9H228, P01375, Q13362, Q9BX95, P10415 | PRKCA, S1PR1, EDG8, TNF, PPP2R5C, SGPP1, BCL2 | More | | Flumazenil | hsa04072 | Phospholipase D signaling pathway | 2.75E-02 | 3 | P61586, O14986, P63092 | RHOA, PIP5K1B, GNAS | More | | Flumazenil | hsa04080 | Neuroactive ligand-receptor interaction | 1.18E-02 | 7 | P08311, Q15722, P21453, Q9H228, O00398, P21462, P21730 | CTSG, LTB4R, S1PR1, EDG8, P2RY10, FPR1, C5AR1 | More | | Flumazenil | hsa04115 | p53 signaling pathway | 3.57E-02 | 5 | P24522, Q13315, Q53FA7, O95067, P10415 | GADD45A, ATM, TP53I3, CCNB2, BCL2 | More | | Flumazenil | hsa04120 | Ubiquitin mediated proteolysis | 4.03E-04 | 7 | Q14145, Q13042, Q13191, Q15751, O95071, Q7Z6Z7, P0CG47 | KEAP1, CDC16, CBLB, HERC1, UBR5, HUWE1, UBB | More | | Flumazenil | hsa04137 | Mitophagy - animal | 6.72E-04 | 4 | P19784, P67870, Q07817, P0CG47 | CSNK2A2, CSNK2B, BCL2L1, UBB | More | | Flumazenil | hsa04145 | Phagosome | 1.90E-04 | 9 | Q15080, P14598, Q13509, P68371, Q13488, P05164, O60603, P35443, P13765 | NCF4, NCF1, TUBB3, TUBB2C, TCIRG1, MPO, TLR2, THBS4, HLA-DOB | More | | Flumazenil | hsa04151 | PI3K-Akt signaling pathway | 3.70E-02 | 12 | P42338, P43657, P20827, P49767, P08238, Q8WYR1, P63218, P50151, O15335, Q13751, P14784, P30281 | PIK3CB, P2RY5, EFNA1, VEGFC, HSP90AB1, PIK3R5, GNG5, GNG10, CHAD, LAMB3, IL2RB, CCND3 | More | | Flumazenil | hsa04210 | Apoptosis | 1.52E-02 | 9 | Q13315, P10415, Q13489, P25963, P01375, P24522, Q16548, Q13077, Q14643 | ATM, BCL2, BIRC3, NFKBIA, TNF, GADD45A, BCL2A1, TRAF1, ITPR1 | More | | Flumazenil | hsa04310 | Wnt signaling pathway | 4.17E-03 | 3 | P61586, P19784, P67870 | RHOA, CSNK2A2, CSNK2B | More | | Flumazenil | hsa04360 | Axon guidance | 2.47E-03 | 7 | P16333, P20827, O95631, P42338, P07332, P23528, P19174 | NCK1, EFNA1, NTN1, PIK3CB, FES, CFL1, PLCG1 | More | | Flumazenil | hsa04371 | Apelin signaling pathway | 1.00E-02 | 7 | P63218, P50151, Q8WYR1, Q14814, Q14344, Q13485, P84022 | GNG5, GNG10, PIK3R5, MEF2D, GNA13, SMAD4, SMAD3 | More | | Flumazenil | hsa04510 | Focal adhesion | 4.07E-02 | 3 | O14986, P61586, Q16363 | PIP5K1B, RHOA, LAMA4 | More | | Flumazenil | hsa04520 | Adherens junction | 1.38E-04 | 3 | P19784, P67870, P61586 | CSNK2A2, CSNK2B, RHOA | More | | Flumazenil | hsa04613 | Neutrophil extracellular trap formation | 1.30E-03 | 13 | P17252, O60603, P05164, P08246, Q9UM07, Q6FI13, P14598, Q15080, P20160, P08311, P49913, P21730, P21462 | PRKCA, TLR2, MPO, ELA2, PADI4, H2AC18; H2AC19, NCF1, NCF4, AZU1, CTSG, CAMP, C5AR1, FPR1 | More | | Flumazenil | hsa04621 | NOD-like receptor signaling pathway | 5.46E-04 | 13 | Q14643, P25963, Q13489, Q9H1Y0, P43490, O00463, P10415, Q05823, P01375, P49913, P59665, P59666, P12838 | ITPR1, NFKBIA, BIRC3, ATG5, PBEF1, TRAF5, BCL2, RNASEL, TNF, CAMP, DEFA1; DEFA1B, DEFA3, DEFA4 | More | | Flumazenil | hsa04659 | Th17 cell differentiation | 2.19E-03 | 9 | P19174, P42224, P14784, P14778, P40189, P84022, Q13485, P08238, P07766 | PLCG1, STAT1, IL2RB, IL1R1, IL6ST, SMAD3, SMAD4, HSP90AB1, CD3E | More | | Flumazenil | hsa04660 | T cell receptor signaling pathway | 4.20E-02 | 7 | P01375, P25963, Q9UDY8, Q04759, P10747, O95267, Q08881 | TNF, NFKBIA, MALT1, PRKCQ, CD28, RASGRP1, ITK | More | | Flumazenil | hsa04662 | B cell receptor signaling pathway | 1.74E-02 | 5 | P42338, P60033, P07948, P21854, Q8N149 | PIK3CB, CD81, LYN, CD72, LILRA2 | More | | Flumazenil | hsa04664 | Fc epsilon RI signaling pathway | 2.47E-02 | 4 | P42338, P07948, P19174, P09917 | PIK3CB, LYN, PLCG1, ALOX5 | More | | Flumazenil | hsa04666 | Fc gamma R-mediated phagocytosis | 2.25E-03 | 6 | P42338, P23528, P06396, O14494, P14598, P17252 | PIK3CB, CFL1, GSN, PLPP1, NCF1, PRKCA | More | | Flumazenil | hsa04668 | TNF signaling pathway | 2.59E-02 | 7 | P01375, O00463, Q13489, P25963, P20749, Q13077, P14780 | TNF, TRAF5, BIRC3, NFKBIA, BCL3, TRAF1, MMP9 | More | | Flumazenil | hsa04670 | Leukocyte transendothelial migration | 4.20E-02 | 7 | P14780, Q96A32, P17252, P14598, Q15080, Q08881, P42681 | MMP9, MYLPF, PRKCA, NCF1, NCF4, ITK, TXK | More | | Flumazenil | hsa04672 | Intestinal immune network for IgA production | 1.62E-02 | 3 | P29965, P10747, P13765 | CD40LG, CD28, HLA-DOB | More | | Flumazenil | hsa04713 | Circadian entrainment | 4.94E-02 | 2 | P62873, P63092 | GNB1, GNAS | More | | Flumazenil | hsa04723 | Retrograde endocannabinoid signaling | 4.94E-02 | 2 | P48169, P62873 | GABRA4, GNB1 | More | | Flumazenil | hsa04724 | Glutamatergic synapse | 3.65E-02 | 2 | P63092, P62873 | GNAS, GNB1 | More | | Flumazenil | hsa04726 | Serotonergic synapse | 2.52E-02 | 2 | P63092, P62873 | GNAS, GNB1 | More | | Flumazenil | hsa04744 | Phototransduction | 2.80E-02 | 2 | P62873, P0DP23 | GNB1, CALM1 | More | | Flumazenil | hsa04914 | Progesterone-mediated oocyte maturation | 3.92E-02 | 3 | P42338, Q13370, P08238 | PIK3CB, PDE3B, HSP90AB1 | More | | Flumazenil | hsa04916 | Melanogenesis | 4.80E-02 | 4 | P0DP23, Q9UJU2, P17252, P04628 | CALM1, LEF1, PRKCA, WNT1 | More | | Flumazenil | hsa04920 | Adipocytokine signaling pathway | 4.49E-02 | 4 | P25963, P33121, Q04759, P01375 | NFKBIA, ACSL1, PRKCQ, TNF | More | | Flumazenil | hsa04924 | Renin secretion | 3.77E-02 | 2 | Q13370, P0DP23 | PDE3B, CALM1 | More | | Flumazenil | hsa04933 | AGE-RAGE signaling pathway in diabetic complications | 3.21E-02 | 5 | P84022, Q13485, P42338, P49767, P19174 | SMAD3, SMAD4, PIK3CB, VEGFC, PLCG1 | More | | Flumazenil | hsa04940 | Type I diabetes mellitus | 1.87E-02 | 2 | P48023, P01375 | FASLG, TNF | More | | Flumazenil | hsa04970 | Salivary secretion | 4.49E-02 | 4 | P22694, Q14643, P17252, P49913 | PRKACB, ITPR1, PRKCA, CAMP | More | | Flumazenil | hsa04972 | Pancreatic secretion | 3.65E-02 | 2 | P63092, P61586 | GNAS, RHOA | More | | Flumazenil | hsa05032 | Morphine addiction | 9.04E-05 | 5 | P62873, P48169, P78334, P63092, P32298 | GNB1, GABRA4, GABRE, GNAS, GRK4 | More | | Flumazenil | hsa05131 | Shigellosis | 3.34E-02 | 11 | P01375, P25963, O00463, Q04759, Q9UDY8, Q9H1Y0, Q14643, Q12778, Q13315, P10415, Q96A32 | TNF, NFKBIA, TRAF5, PRKCQ, MALT1, ATG5, ITPR1, FOXO1, ATM, BCL2, MYLPF | More | | Flumazenil | hsa05132 | Salmonella infection | 3.41E-03 | 13 | P51617, P25963, P01375, Q9UJU2, Q13489, P10415, O75369, Q96A32, O60603, Q9BQS8, Q13561, Q13509, P68371 | IRAK1, NFKBIA, TNF, LEF1, BIRC3, BCL2, FLNB, MYLPF, TLR2, FYCO1, DCTN2, TUBB3, TUBB2C | More | | Flumazenil | hsa05140 | Leishmaniasis | 1.18E-02 | 7 | P14598, P13765, O60603, P25963, P01375, P51617, Q15080 | NCF1, HLA-DOB, TLR2, NFKBIA, TNF, IRAK1, NCF4 | More | | Flumazenil | hsa05142 | Chagas disease | 2.26E-02 | 3 | P01375, P30679, P48023 | TNF, GNA15, FASLG | More | | Flumazenil | hsa05143 | African trypanosomiasis | 2.72E-02 | 2 | P01375, P48023 | TNF, FASLG | More | | Flumazenil | hsa05145 | Toxoplasmosis | 3.07E-02 | 7 | P51617, P25963, P01375, P10415, Q13489, P13765, O60603 | IRAK1, NFKBIA, TNF, BCL2, BIRC3, HLA-DOB, TLR2 | More | | Flumazenil | hsa05150 | Staphylococcus aureus infection | 1.83E-02 | 3 | P59665, P59666, P12838 | DEFA1; DEFA1B, DEFA3, DEFA4 | More | | Flumazenil | hsa05152 | Tuberculosis | 5.88E-04 | 11 | Q13488, P0DP23, P48382, O60603, P01375, P10415, P13765, P01568, P49913, Q9UDY8, P51617 | TCIRG1, CALM1, RFX5, TLR2, TNF, BCL2, HLA-DOB, IFNA21, CAMP, MALT1, IRAK1 | More | | Flumazenil | hsa05161 | Hepatitis B | 2.33E-02 | 8 | P17252, P14780, P25963, P01375, P10415, P51617, O60603, Q14765 | PRKCA, MMP9, NFKBIA, TNF, BCL2, IRAK1, TLR2, STAT4 | More | | Flumazenil | hsa05163 | Human cytomegalovirus infection | 2.09E-02 | 4 | P62873, P61586, P63092, P61769 | GNB1, RHOA, GNAS, B2M | More | | Flumazenil | hsa05168 | Herpes simplex virus 1 infection | 1.15E-02 | 8 | P42224, Q07955, Q01130, Q13243, P42338, Q13398, Q03923, Q9UDV6 | STAT1, SFRS1, SFRS2, SFRS5, PIK3CB, ZNF211, ZNF85, ZNF212 | More | | Flumazenil | hsa05170 | Human immunodeficiency virus 1 infection | 2.13E-05 | 17 | P62873, P0DP23, P01375, P17252, O00463, Q14643, P01568, P51617, P25963, O60603, Q13315, O95067, P23528, P10415, Q13619, Q93034, Q9Y6Q5 | GNB1, CALM1, TNF, PRKCA, TRAF5, ITPR1, IFNA21, IRAK1, NFKBIA, TLR2, ATM, CCNB2, CFL1, BCL2, CUL4A, CUL5, AP1M2 | More | | Flumazenil | hsa05171 | Coronavirus disease - COVID-19 | 4.47E-02 | 2 | Q9UHA3, O14786 | RSL24D1, NRP1 | More | | Flumazenil | hsa05200 | Pathways in cancer | 1.31E-03 | 21 | Q13751, P42338, P08238, P42224, P19174, P43246, P84022, Q13485, Q13547, P14923, P30281, P49767, P43657, P63218, P50151, Q14344, Q7LDG7, O75293, P0DP23, P14784, P40189 | LAMB3, PIK3CB, HSP90AB1, STAT1, PLCG1, MSH2, SMAD3, SMAD4, HDAC1, JUP, CCND3, VEGFC, P2RY5, GNG5, GNG10, GNA13, RASGRP2, GADD45B, CALM1, IL2RB, IL6ST | More | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
---|
P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | Q13751 | LAMB3 | Laminin subunit beta-3 | 0.844 | P29375 | JARID1A | Lysine-specific demethylase 5A | P42338 | PIK3CB | Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform | -0.79 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P42338 | PIK3CB | Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform | 0.777 | P29375 | JARID1A | Lysine-specific demethylase 5A | P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | 0.711 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | -0.823 | P29375 | JARID1A | Lysine-specific demethylase 5A | P42224 | STAT1 | Signal transducer and activator of transcription 1-alpha/beta | 0.764 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P19174 | PLCG1 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | -0.766 | P29375 | JARID1A | Lysine-specific demethylase 5A | P43246 | MSH2 | DNA mismatch repair protein Msh2 | 0.87 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P43246 | MSH2 | DNA mismatch repair protein Msh2 | -0.811 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P84022 | SMAD3 | Mothers against decapentaplegic homolog 3 | 0.725 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | Q13485 | SMAD4 | Mothers against decapentaplegic homolog 4 | -0.746 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | Q13547 | HDAC1 | Histone deacetylase 1 | -0.754 | P29375 | JARID1A | Lysine-specific demethylase 5A | P14923 | JUP | Junction plakoglobin | -0.735 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P30281 | CCND3 | G1/S-specific cyclin-D3 | 0.743 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P49767 | VEGFC | Vascular endothelial growth factor C | 0.743 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P43657 | P2RY5 | Lysophosphatidic acid receptor 6 | -0.735 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P63218 | GNG5 | Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-5 | 0.941 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P50151 | GNG10 | Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-10 | 0.948 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | Q14344 | GNA13 | Guanine nucleotide-binding protein subunit alpha-13 | 0.87 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | Q7LDG7 | RASGRP2 | RAS guanyl-releasing protein 2 | 0.704 | P29375 | JARID1A | Lysine-specific demethylase 5A | O75293 | GADD45B | Growth arrest and DNA damage-inducible protein GADD45 beta | -0.748 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | O75293 | GADD45B | Growth arrest and DNA damage-inducible protein GADD45 beta | 0.731 | P29375 | JARID1A | Lysine-specific demethylase 5A | P0DP23 | CALM1 | Calmodulin-1 | 0.755 | P29375 | JARID1A | Lysine-specific demethylase 5A | P14784 | IL2RB | Interleukin-2 receptor subunit beta | 0.768 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P14784 | IL2RB | Interleukin-2 receptor subunit beta | -0.835 | P29375 | JARID1A | Lysine-specific demethylase 5A | P40189 | IL6ST | Interleukin-6 receptor subunit beta | 0.83 |
| Flumazenil | hsa05202 | Transcriptional misregulation in cancer | 2.43E-05 | 14 | Q12778, Q15532, Q13315, P14780, P14923, Q16548, Q13489, Q13077, P35226, P05164, P12838, P08246, Q9C0K0, P24522 | FOXO1, SS18, ATM, MMP9, JUP, BCL2A1, BIRC3, TRAF1, BMI1, MPO, DEFA4, ELA2, BCL11B, GADD45A | More | | Flumazenil | hsa05205 | Proteoglycans in cancer | 1.09E-02 | 10 | Q13009, Q12955, Q14643, O75369, P14780, P17252, O60603, P04628, Q13635, P08962 | TIAM1, ANK3, ITPR1, FLNB, MMP9, PRKCA, TLR2, WNT1, PTCH1, CD63 | More | | Flumazenil | hsa05212 | Pancreatic cancer | 2.14E-03 | 5 | P42338, P42224, P84022, Q13485, O75293 | PIK3CB, STAT1, SMAD3, SMAD4, GADD45B | More | | Flumazenil | hsa05214 | Glioma | 1.72E-02 | 3 | P0DP23, P42338, O75293 | CALM1, PIK3CB, GADD45B | More | | Flumazenil | hsa05220 | Chronic myeloid leukemia | 2.16E-02 | 5 | Q13547, Q13485, P84022, P42338, O75293 | HDAC1, SMAD4, SMAD3, PIK3CB, GADD45B | More | | Flumazenil | hsa05222 | Small cell lung cancer | 2.79E-02 | 6 | Q13489, P10415, P25963, Q13077, O00463, P24522 | BIRC3, BCL2, NFKBIA, TRAF1, TRAF5, GADD45A | More | | Flumazenil | hsa05310 | Asthma | 3.88E-02 | 3 | P13765, P12724, P01375 | HLA-DOB, RNASE3, TNF | More | | Flumazenil | hsa05320 | Autoimmune thyroid disease | 8.64E-03 | 4 | P13765, P29965, P01568, P10747 | HLA-DOB, CD40LG, IFNA21, CD28 | More | | Flumazenil | hsa05321 | Inflammatory bowel disease | 1.28E-02 | 5 | O60603, P01375, P13765, Q14765, P23771 | TLR2, TNF, HLA-DOB, STAT4, GATA3 | More | | Flumazenil | hsa05322 | Systemic lupus erythematosus | 4.20E-02 | 7 | P08246, P08311, P01375, P10747, P13765, Q6FI13, P05455 | ELA2, CTSG, TNF, CD28, HLA-DOB, H2AC18; H2AC19, SSB | More | | Flumazenil | hsa05330 | Allograft rejection | 2.72E-02 | 2 | P48023, P01375 | FASLG, TNF | More | | Flumazenil | hsa05332 | Graft-versus-host disease | 8.44E-04 | 6 | P13765, P48023, P10747, P01375, P26715, Q13241 | HLA-DOB, FASLG, CD28, TNF, KLRC1, KLRD1 | More | | Flumazenil | hsa05418 | Fluid shear stress and atherosclerosis | 3.73E-02 | 4 | P42338, P14598, P0DP23, P08238 | PIK3CB, NCF1, CALM1, HSP90AB1 | More | | |